Recent share performance and context

Crinetics Pharmaceuticals (CRNX) has drawn investor attention after recent trading left the stock with a 0.5% decline over the past day and a 6.5% decline over the past week.

Those short term moves sit alongside a 14% gain over the past month and a 27% decline over the past 3 months. Together they present a mixed recent performance picture to weigh against the company’s clinical stage pipeline.

At the current share price of $38.33, Crinetics shows a mix of near term weakness and longer term strength, with recent share price declines contrasting with a positive 1 year total shareholder return of 18.34% and a 5 year total shareholder return of 121.43% that reflects shifting expectations around its clinical pipeline and risk profile.

If Crinetics has you looking more closely at healthcare and therapy development, it can be useful to see what else is moving in the space via 33 healthcare AI stocks.

With Crinetics trading at $38.33 and recent returns painting a mixed picture, the key question now is simple: is the current price overlooking the company’s pipeline potential, or already factoring in expectations for future growth?

Most Popular Narrative: 53.5% Undervalued

The most followed narrative puts Crinetics’ fair value at $82.43 per share, well above the recent $38.33 close, and builds a detailed case around future revenue and margins.

The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.

Want to understand why this narrative supports such a large gap to today’s price? It leans on aggressive revenue expansion, margin improvement and a rich future earnings multiple. Curious which specific assumptions push the fair value above $80 and how sensitive that is to execution in rare endocrine diseases? The full narrative sets out those moving parts in detail.

Result: Fair Value of $82.43 (UNDERVALUED)

However, this optimistic setup could be shaken if PALSONIFY uptake lags early expectations or if further pipeline delays emerge after the Graves’ disease and ADPKD setbacks.

Next Steps

With mixed opinions around risk and reward running through this story, it makes sense to check the details yourself and then move quickly to shape your own view using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Crinetics has sharpened your interest, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target potential future income by scanning companies with resilient payouts through the 13 dividend fortresses.
• Look for quality at a measured price using the 54 high quality undervalued stocks to see where fundamentals and pricing line up.
• Spot less crowded opportunities by checking the screener containing 25 high quality undiscovered gems, where proven fundamentals have not yet attracted broad attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.